In the patients with platinum-resistant ovarian cancer, combination treatment of a pan-AKT inhibitor Afursertib, Carboplatin and Paclitaxel were efficacious with an object response rate (ORR) at 32.1% [25]. This evidence concerns the gene AKT1 and ovarian cancer.